Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for MRD in Pediatric B-cell Precursor ALL
NCT04604691Phase 1Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of blinatumomab in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), sponsored by Seoul National University Hospital. Primary endpoint: Safety evaluation including cytokine release syndrome at 30 days. Status: unknown.
02
Drugs
blinatumomab
03
Conditions
B-cell precursor acute lymphoblastic leukemia (BCP-ALL)
Beyond the preview
Go deeper on NCT04604691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604691.